1 |
Cuchet-Lourenco D, Vanni E, Glass M, et al (2012). Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation. J Virol, 86, 11209-22.
DOI
|
2 |
de Stanchina E, Querido E, Narita M, et al (2004). PML is a direct p53 target that modulates p53 effector functions. Molecular cell, 13, 523-35.
DOI
|
3 |
de The H CC, Lanotte M, Degos L, Dejean A (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Natur, 347, 558-61.
DOI
ScienceOn
|
4 |
de Visser KE, Coussens LM (2006). The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol, 13, 118-37.
|
5 |
Dellaire G, Ching RW, Ahmed K, et al (2006b). Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol, 175, 55-66.
DOI
|
6 |
Fanelli M, Fantozzi A, De Luca P, et al (2004). The coiledcoil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J Biol Chem, 279, 5374-9.
DOI
|
7 |
Dermime S, Bertazzoli C, Marchesi E, et al (1996). Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res, 2, 593-600.
|
8 |
Dyck JA, Maul GG, Miller WH, Jr., et al (1994). A novel macromolecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein. Cell, 76, 333-43.
DOI
|
9 |
Bischof O, Kirsh O, Pearson M, et al (2002). Deconstructing PML-induced premature senescence. Embo J, 21, 3358-69.
DOI
|
10 |
Ben-Baruch A (2006). The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev, 25, 357-71.
DOI
|
11 |
Bernardi R, Guernah I, Jin D, et al (2006). PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature, 442, 779-85.
DOI
|
12 |
Bernardi R, Pandolfi PP (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol, 8, 1006-16.
DOI
|
13 |
Best JL, Ganiatsas S, Agarwal S, et al (2002). SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell, 10, 843-55.
DOI
|
14 |
Carbone R, Pearson M, Minucci S, et al (2002). PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene, 21, 1633-40.
DOI
|
15 |
Chen RH, Lee YR, Yuan WC (2012). The role of PML ubiquitination in human malignancies. J Biomed Sci, 19, 81.
DOI
|
16 |
Carracedo A, Weiss D, Leliaert AK, et al (2012). A metabolic prosurvival role for< i> PML in breast cancer. J clin Invest, 122, 3088-100.
DOI
|
17 |
Chang CC, Naik MT, Huang YS, et al (2011). Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation. Mol Cell, 42, 62-74.
DOI
|
18 |
Chelbi-Alix M, Pelicano L, Quignon F, et al (1995). Induction of the PML protein by interferons in normal and APL cells. Leukemia, 9, 2027-33.
|
19 |
Cooke HJ, Smith BA (1986). Variability at the telomeres of the human X/Y pseudoautosomal region. Cold Spring Harb Symp Quant Biol, 51, 213-9.
DOI
|
20 |
Everett RD (2001). DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene, 20, 7266-73.
DOI
|
21 |
Gamell C, Jan Paul P, Haupt Y, et al (2014). PML tumour suppression and beyond: Therapeutic implications. FEBS Lett.
|
22 |
Geoffroy MC, Jaffray EG, Walker KJ, et al (2010). Arsenicinduced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell, 21, 4227-39.
DOI
|
23 |
Ghafouri-Fard S, Ghafouri-Fard S (2012a). Immunotherapy in nonmelanoma skin cancer. Immunotherapy, 4, 499-510.
DOI
ScienceOn
|
24 |
Ghafouri-Fard S, Ghafouri-Fard S (2012b). siRNA and cancer immunotherapy. Immunotherapy, 4, 907-17.
DOI
|
25 |
Ghafouri-Fard S, Modarressi MH, Yazarloo F (2012). Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity. Ann. Saudi Med, 32, 256-61.
|
26 |
Ghafouri-Fard S, Shamsi R, Seifi-Alan M, et al (2014). Cancertestis genes as candidates for immunotherapy in breast cancer. Immunotherapy, 6, 165-79.
DOI
|
27 |
Hattersley N, Shen L, Jaffray EG, et al (2011). The SUMO protease SENP6 is a direct regulator of PML nuclear bodies. Mol Biol Cell, 22, 78-90.
DOI
|
28 |
Guan D, Factor D, Liu Y, et al (2013). The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein. Oncogene, 32, 3819-28.
DOI
|
29 |
Guo A, Salomoni P, Luo J, et al (2000). The function of PML in p53-dependent apoptosis. Nat Cell Biol, 2, 730-6.
DOI
|
30 |
Gurrieri C, Capodieci P, Bernardi R, et al (2004). Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst, 96, 269-79.
DOI
|
31 |
Hubackova S, Krejcikova K, Bartek J, et al (2012). Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J Biol Chem, 287, 26702-14.
DOI
|
32 |
Ishov AM, Sotnikov AG, Negorev D, et al (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol, 147, 221-34.
DOI
|
33 |
Ito K, Bernardi R, Morotti A, et al (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 453, 1072-8.
DOI
|
34 |
Jensen K, Shiels C, Freemont PS (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene, 20, 7223-33.
DOI
|
35 |
Jin G, Wang Y-J, Lin H-K (2013). Emerging cellular functions of cytoplasmic PML. Frontiers in oncology, 3, 147.
|
36 |
Kakizuka A, Miller WH, Jr., Umesono K, et al (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66, 663-74.
DOI
ScienceOn
|
37 |
Lallemand-Breitenbach V, de The H (2010). PML nuclear bodies. Cold Spring Harb Perspect Biol, 2, 000661.
DOI
|
38 |
Kamitani T, Kito K, Nguyen HP, et al (1998). Identification of three major sentrinization sites in PML. J Biol Chem, 273, 26675-82.
DOI
|
39 |
Kim HJ, Song DE, Lim SY, et al (2011). Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes. PLoS One, 6, 26264.
DOI
|
40 |
Koken MH, Puvion-Dutilleul F, Guillemin MC, et al (1994). The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. Embo J, 13, 1073-83.
|
41 |
Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al (2008). Arsenic degrades PML or PML-RARalpha through a SUMOtriggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol, 10, 547-55.
DOI
|
42 |
Lee EY, Lee ZH, Song YW (2009). CXCL10 and autoimmune diseases. Autoimmun Rev, 8, 379-83.
DOI
|
43 |
Lee HE, Jee CD, Kim MA, et al (2007). Loss of promyelocytic leukemia protein in human gastric cancers. Cancer letters, 247, 103-9.
DOI
|
44 |
Lin H-K, Bergmann S, Pandolfi PP (2004). Cytoplasmic PML function in TGF- signalling. Nature, 431, 205-11.
DOI
|
45 |
Maarifi G, Chelbi-Alix MK, Nisole S (2014). PML control of cytokine signaling. Cytokine Growth Factor Rev.
|
46 |
Maiuri MC, Tasdemir E, Criollo A, et al (2009). Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ, 16, 87-93.
DOI
ScienceOn
|
47 |
Mallette FA, Goumard S, Gaumont-Leclerc MF, et al (2004). Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene, 23, 91-9.
DOI
ScienceOn
|
48 |
Nakamura TM, Morin GB, Chapman KB, et al (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science, 277, 955-9.
DOI
|
49 |
Martin N, Benhamed M, Nacerddine K, et al (2012). Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence. Embo J, 31, 95-109.
DOI
|
50 |
Mazza M, Pelicci PG (2013). Is PML a Tumor Suppressor? Front Oncol, 3, 174.
|
51 |
Osman Y, Takahashi M, Zheng Z, et al (1999). Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res, 18, 485-92.
|
52 |
Meyerson M, Counter CM, Eaton EN, et al (1997). hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90, 785-95.
DOI
ScienceOn
|
53 |
Nicewonger J, Suck G, Bloch D, et al (2004). Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression. J Virol, 78, 9412-22.
DOI
ScienceOn
|
54 |
Nisole S, Maroui MA, Mascle XH, et al (2013). Differential Roles of PML Isoforms. Front Oncol, 3, 125.
|
55 |
Padua RA, Larghero J, Robin M, et al (2003). PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nature medicine, 9, 1413-7.
DOI
|
56 |
Potts PR, Yu H (2007). The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol, 14, 581-90.
DOI
|
57 |
Quignon F, De Bels F, Koken M, et al (1998). PML induces a novel caspase-independent death process. Nat Genet, 20, 259-65.
DOI
ScienceOn
|
58 |
Salomoni P, Dvorkina M, Michod D (2012). Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis, 3, 247.
DOI
|
59 |
Rabellino A, Carter B, Konstantinidou G, et al (2012). The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res, 72, 2275-84.
DOI
|
60 |
Reineke EL, Kao HY (2009). PML: An emerging tumor suppressor and a target with therapeutic potential. Cancer Ther, 7, 219-26.
|
61 |
Shen TH, Lin HK, Scaglioni PP, et al (2006). The mechanisms of PML-nuclear body formation. Mol Cell, 24, 331-9.
DOI
|
62 |
Reineke EL, Liu Y, Kao H-Y (2010). Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J Biol Chem, 285, 9485-92.
DOI
|
63 |
Satow R, Shitashige M, Jigami T, et al (2012). beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells. Gastroenterology, 142, 572-81.
DOI
|
64 |
Scaglioni PP, Yung TM, Choi S, et al (2008). CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem, 316, 149-54.
DOI
|
65 |
Silzle T, Randolph GJ, Kreutz M, et al (2004). The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer, 108, 173-80.
DOI
|
66 |
Stadler M, Chelbi-Alix MK, Koken M, et al (1995). Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene, 11, 2565-73.
|
67 |
Stehmeier P, Muller S (2009). Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell, 33, 400-9.
DOI
|
68 |
Tatham MH, Geoffroy MC, Shen L, et al (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol, 10, 538-46.
DOI
|
69 |
Tabarestani S, Ghafouri-Fard S (2012). Cancer stem cells and response to therapy. Asian Pac J Cancer Prev, 13, 5951-8.
|
70 |
Tamura G (2006). Alterations of tumor suppressor and tumorrelated genes in the development and progression of gastric cancer. World J Gastroenterol, 12, 192-8.
|
71 |
Vernier M, Bourdeau V, Gaumont-Leclerc MF, et al (2011). Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev, 25, 41-50.
DOI
|
72 |
Tang MK, Liang YJ, Chan JY, et al (2013). Promyelocytic leukemia (PML) protein plays important roles in regulating cell adhesion, morphology, proliferation and migration. PLoS One, 8, 59477.
DOI
|
73 |
Trotman LC, Alimonti A, Scaglioni PP, et al (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441, 523-7.
DOI
|
74 |
Van Damme E, Laukens K, Dang TH, et al (2010). A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci, 6, 51-67.
|
75 |
Wang S, Long J, Zheng CF (2012). The potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1. Protein Cell, 3, 372-82.
DOI
|
76 |
Wang Z-G, Ruggero D, Ronchetti S, et al (1998a). PML is essential for multiple apoptotic pathways. Nature genetics, 20, 266-72.
DOI
|
77 |
Wang ZG, Ruggero D, Ronchetti S, et al (1998b). PML is essential for multiple apoptotic pathways. Nat Genet, 20, 266-72.
DOI
|
78 |
Yang S, Kuo C, Bisi JE, et al (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol, 4, 865-70.
DOI
ScienceOn
|
79 |
Wu G, Lee WH, Chen PL (2000). NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem, 275, 30618-22.
DOI
|
80 |
Wu S, Zhang X, Li ZM, et al (2013). Partial Least Squares Based Gene Expression Analysis in EBV- Positive and EBVNegative Posttransplant Lymphoproliferative Disorders. Asian Pac J Cancer Prev, 14, 6347-50.
DOI
ScienceOn
|
81 |
Wu WS, Xu ZX, Hittelman WN, et al (2003). Promyelocytic leukemia protein sensitizes tumor necrosis factor alphainduced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem, 278, 12294-304.
DOI
|
82 |
Yeager TR, Neumann AA, Englezou A, et al (1999). Telomerasenegative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res, 59, 4175-9.
|
83 |
Zhou W, Bao S (2014). PML-mediated signaling and its role in cancer stem cells. Oncogene, 33, 1475-84.
DOI
|